Hyundai Feed

HYUNDAI FEED Inc. engages in the manufacture and sale of formulated feed. Its primary products include poultry and pig feed. The company also engages in the biopharmaceutical business. In addition, it focuses on the development and commercialization of immunotherapies for cancer. Further, the company's lead product includes oregovomab, an immunotherapy for ovarian cancer. Additionally, it is involved in the developing AR20.5, which treatment of pancreatic cancer. The company was formerly known as CANARIABIO Inc. and changed to HYUNDAI FEED Inc. on January 2024. The company was founded in 1983 and is headquartered in Seoul, South Korea.